# Clinical Trials Data EGFR - Document 127

# Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

## Clinical Trial: https://clinicaltrials.gov/study/NCT00939523

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Patients with nonfunctioning adenomas who have undergone at least one prior surgical resection and have demonstrated recurrence on MRI\n\* Patients with prolactinomas who are resistant to dopamine agonist therapy\n\* Patients with malignant pituitary tumors\n\* Patients with visual field deficits and/or compression of the optic chiasm must be stable for at least 6 months\n\nExclusion Criteria:\n\n\* Patients with compromised visual fields and/or compression of the optic chiasm on MRI that has not been stable for last 6 months.\n\* Patients that have reduced left ventricular ejection fraction less than 50%\n\* Patients with moderate to severe hepatic impairment\n\* Patients that are pregnant or lactating\n\* Patients under the age of 18\n\* Active hepatitis\n\* Known previous HIV Positive\n\* Concurrent cancers\n\* Life expectancy less than one year",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, there is no specific mention of EGFR gene mutations as either an inclusion or exclusion criterion. The eligibility criteria focus on the type of pituitary tumors, their treatment resistance, and other medical conditions or characteristics of the patients. Therefore, having an EGFR gene mutation is neither a specific inclusion nor an exclusion factor according to the criteria you've provided.  
  
To determine eligibility precisely, it would be necessary to confirm with the clinical trial organizers whether an EGFR gene mutation would affect participation based on other undisclosed criteria or considerations specific to the study objectives. However, based on the given criteria alone, an EGFR gene mutation does not explicitly make a patient ineligible.